# QBitaLabs Financial Projections

**CONFIDENTIAL | Version 1.0 | January 2026**

---

## Financial Summary

### 5-Year Revenue Forecast

| Year | ARR | Growth | Customers | ARPC |
|------|-----|--------|-----------|------|
| 2026 | $5M | - | 5 | $1M |
| 2027 | $20M | 300% | 15 | $1.3M |
| 2028 | $60M | 200% | 35 | $1.7M |
| 2029 | $150M | 150% | 60 | $2.5M |
| 2030 | $500M | 233% | 100+ | $5M |

*ARPC = Average Revenue Per Customer*

---

## Revenue Model Breakdown

### Revenue by Product Line

| Product | 2026 | 2027 | 2028 | 2029 | 2030 |
|---------|------|------|------|------|------|
| QBita Discovery | $3M | $12M | $35M | $80M | $250M |
| QBita Twin | $1M | $4M | $15M | $40M | $125M |
| QBita Longevity | $0.5M | $2M | $5M | $15M | $60M |
| QBita Analytics | $0.5M | $2M | $5M | $15M | $65M |
| **Total** | **$5M** | **$20M** | **$60M** | **$150M** | **$500M** |

### Revenue by Type

| Stream | 2026 | 2027 | 2028 | 2029 | 2030 |
|--------|------|------|------|------|------|
| Platform SaaS | 30% | 35% | 40% | 43% | 45% |
| Per-Molecule/Use Fees | 40% | 35% | 30% | 27% | 25% |
| Professional Services | 25% | 20% | 18% | 15% | 15% |
| Licensing/Royalties | 5% | 10% | 12% | 15% | 15% |

### Revenue by Customer Segment

| Segment | 2026 | 2027 | 2028 | 2029 | 2030 |
|---------|------|------|------|------|------|
| Pharma (Top 50) | 60% | 55% | 50% | 45% | 40% |
| Biotech | 15% | 20% | 25% | 25% | 25% |
| Health Systems | 15% | 15% | 15% | 18% | 20% |
| Clinics/Providers | 5% | 5% | 5% | 7% | 10% |
| Academic/Other | 5% | 5% | 5% | 5% | 5% |

---

## Expense Projections

### Operating Expenses

| Category | 2026 | 2027 | 2028 | 2029 | 2030 |
|----------|------|------|------|------|------|
| R&D | $12M | $20M | $30M | $45M | $75M |
| Sales & Marketing | $6M | $12M | $22M | $40M | $100M |
| G&A | $4M | $6M | $10M | $18M | $40M |
| Cloud/Infrastructure | $3M | $7M | $13M | $22M | $60M |
| **Total OpEx** | **$25M** | **$45M** | **$75M** | **$125M** | **$275M** |

### Cost of Revenue (COGS)

| Component | 2026 | 2027 | 2028 | 2029 | 2030 |
|-----------|------|------|------|------|------|
| Cloud Computing | $1M | $3M | $8M | $18M | $50M |
| Quantum Credits | $0.5M | $2M | $5M | $12M | $35M |
| Customer Success | $0.25M | $1M | $2M | $5M | $15M |
| **Total COGS** | **$1.75M** | **$6M** | **$15M** | **$35M** | **$100M** |

### Gross Margin

| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|--------|------|------|------|------|------|
| Revenue | $5M | $20M | $60M | $150M | $500M |
| COGS | $1.75M | $6M | $15M | $35M | $100M |
| Gross Profit | $3.25M | $14M | $45M | $115M | $400M |
| **Gross Margin** | **65%** | **70%** | **75%** | **77%** | **80%** |

---

## Profitability Analysis

### EBITDA Bridge

| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|--------|------|------|------|------|------|
| Revenue | $5M | $20M | $60M | $150M | $500M |
| Gross Profit | $3.25M | $14M | $45M | $115M | $400M |
| OpEx | ($25M) | ($45M) | ($75M) | ($125M) | ($275M) |
| **EBITDA** | **($21.75M)** | **($31M)** | **($30M)** | **($10M)** | **$125M** |
| EBITDA Margin | -435% | -155% | -50% | -7% | 25% |

### Path to Profitability

- **Break-even**: Q4 2028 (~$60M ARR)
- **Cash flow positive**: Q2 2029
- **EBITDA positive**: Q4 2029

---

## Headcount Plan

### By Function

| Department | 2026 | 2027 | 2028 | 2029 | 2030 |
|------------|------|------|------|------|------|
| Engineering | 18 | 35 | 55 | 80 | 120 |
| Science/Research | 6 | 12 | 20 | 30 | 50 |
| Sales | 4 | 10 | 20 | 35 | 70 |
| Marketing | 2 | 5 | 10 | 20 | 40 |
| Customer Success | 2 | 4 | 8 | 15 | 30 |
| G&A | 3 | 4 | 7 | 10 | 15 |
| Executive | 5 | 8 | 10 | 10 | 12 |
| **Total** | **35** | **70** | **120** | **200** | **350** |

### Average Cost per Employee

| Category | 2026 | 2027 | 2028 | 2029 | 2030 |
|----------|------|------|------|------|------|
| Engineering | $200K | $210K | $220K | $230K | $240K |
| Science | $180K | $190K | $200K | $210K | $220K |
| Sales | $175K | $185K | $195K | $205K | $215K |
| Other | $140K | $150K | $160K | $170K | $180K |

*Fully loaded cost including salary, benefits, equity, taxes*

---

## Unit Economics

### Customer Economics

| Metric | 2026 | 2028 | 2030 | Target |
|--------|------|------|------|--------|
| CAC | $200K | $180K | $150K | <$150K |
| LTV | $2M | $3M | $5M | >$5M |
| LTV/CAC | 10x | 17x | 33x | >10x |
| Payback Period | 24 mo | 18 mo | 12 mo | <18 mo |

### Customer Acquisition

| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|--------|------|------|------|------|------|
| New Customers | 5 | 10 | 20 | 25 | 40 |
| Churned | 0 | 0 | 2 | 3 | 5 |
| Net New | 5 | 10 | 18 | 22 | 35 |
| **Total Customers** | **5** | **15** | **33** | **55** | **90** |

### Revenue Retention

| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|--------|------|------|------|------|------|
| Gross Retention | 100% | 100% | 95% | 95% | 95% |
| Net Revenue Retention | 150% | 145% | 140% | 140% | 140% |
| Expansion Revenue | $0 | $5M | $15M | $40M | $150M |

---

## Funding Requirements

### Series A ($25M)

**Use of Funds**

| Category | Amount | % | Purpose |
|----------|--------|---|---------|
| R&D | $12M | 48% | Quantum platform, ML models |
| Sales & Marketing | $6M | 24% | Team, content, events |
| Infrastructure | $4M | 16% | Cloud, security, compliance |
| Operations | $3M | 12% | Hiring, G&A |
| **Total** | **$25M** | **100%** | 18-24 month runway |

**Milestones to Achieve**

- [ ] $10M ARR
- [ ] 15 paying customers
- [ ] 3 Fortune 500 logos
- [ ] FDA breakthrough designation
- [ ] Key patents granted
- [ ] 70+ employees

### Future Rounds

| Round | Amount | Timing | Pre-Money | Dilution |
|-------|--------|--------|-----------|----------|
| Series A | $25M | Now | $75M | 25% |
| Series B | $75M | Q2 2027 | $225M | 25% |
| Series C | $150M | Q2 2028 | $500M | 23% |
| Pre-IPO | $300M | Q2 2029 | $1.2B | 20% |

### Cash Flow Forecast

| Quarter | Beginning | Raise | Burn | Ending |
|---------|-----------|-------|------|--------|
| Q1 2026 | $5M | $25M | ($5M) | $25M |
| Q2 2026 | $25M | $0 | ($6M) | $19M |
| Q3 2026 | $19M | $0 | ($6M) | $13M |
| Q4 2026 | $13M | $0 | ($6M) | $7M |
| Q1 2027 | $7M | $75M | ($8M) | $74M |
| ... | ... | ... | ... | ... |

---

## Key Assumptions

### Revenue Assumptions

| Assumption | Value | Source |
|------------|-------|--------|
| Pharma deal size | $500K-$2M | Industry benchmarks |
| Sales cycle | 6-9 months | Enterprise SaaS |
| Win rate | 25% | Conservative |
| Expansion rate | 40% annually | SaaS benchmarks |
| Churn rate | 5% | Enterprise SaaS |

### Cost Assumptions

| Assumption | Value | Source |
|------------|-------|--------|
| Cloud cost/customer | 10% of revenue | Industry average |
| Quantum cost/customer | 7% of revenue | Current pricing |
| Sales comp ratio | 50% of quota | Tech industry |
| Quota per rep | $1.5M | Enterprise SaaS |

### Market Assumptions

| Assumption | Value | Source |
|------------|-------|--------|
| Quantum market CAGR | 52% | McKinsey |
| AI drug discovery CAGR | 40% | BCG |
| Digital health CAGR | 15% | Rock Health |
| Our market share 2030 | 1% of TAM | Conservative |

---

## Sensitivity Analysis

### Revenue Sensitivity

| Scenario | 2028 ARR | 2030 ARR | Notes |
|----------|----------|----------|-------|
| Base case | $60M | $500M | Plan assumptions |
| Conservative | $40M | $300M | 33% lower win rates |
| Aggressive | $90M | $750M | 50% faster expansion |
| Downside | $25M | $150M | Major market headwinds |

### Burn Sensitivity

| Variable | Impact | Mitigation |
|----------|--------|------------|
| +20% headcount cost | +$5M burn/year | Offshore engineering |
| +30% cloud costs | +$3M burn/year | Multi-cloud optimization |
| 6-month sales cycle extension | +$3M burn/year | Pilot-first approach |
| 50% lower win rate | +$10M needed | Focus on fewer deals |

---

## Valuation Analysis

### Comparable Companies

| Company | Stage | Revenue | Valuation | Multiple |
|---------|-------|---------|-----------|----------|
| Recursion | Public | $350M | $3.5B | 10x |
| SchrÃ¶dinger | Public | $300M | $3B | 10x |
| Insilico | Private | $150M | $1.5B | 10x |
| IonQ | Public | $50M | $3B | 60x |
| Tempus | Private | $800M | $8B | 10x |

### QBitaLabs Valuation

| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|--------|------|------|------|------|------|
| Revenue | $5M | $20M | $60M | $150M | $500M |
| Multiple | 20x | 15x | 12x | 10x | 10x |
| **Valuation** | **$100M** | **$300M** | **$720M** | **$1.5B** | **$5B** |

*Multiples reflect quantum premium + healthcare market*

### Return Analysis (Series A)

| Exit Scenario | Valuation | Ownership | Return |
|---------------|-----------|-----------|--------|
| Base case 2030 | $5B | 20% | $1B (40x) |
| M&A 2028 | $1B | 22% | $220M (8.8x) |
| IPO 2029 | $2B | 21% | $420M (16.8x) |
| Downside 2028 | $300M | 22% | $66M (2.6x) |

---

## Appendix: Detailed Models

### A. Monthly Cash Flow Model
*[Available in spreadsheet]*

### B. Cohort Analysis
*[Customer cohort revenue model]*

### C. Hiring Plan by Role
*[Detailed quarterly hiring]*

### D. Scenario Models
*[Full sensitivity analysis]*

---

*Financial projections are forward-looking and subject to significant uncertainty. Actual results may differ materially.*
